Skip to content
Inciteful Med
Resources About us Ask a Question

What Are the Best MCAS Treatments for hEDS Patients?

Published: | Updated:

MCAS treatment in hEDS patients requires continuous, preventative daily medication rather than episodic rescue therapies. The standard protocol begins with a combination of H1 and H2 antihistamines, often at high doses, followed by mast cell stabilizers like cromolyn sodium or ketotifen.

Key Takeaways

  • • Treating MCAS requires continuous, preventative daily medication rather than episodic rescue therapies.
  • • A daily combination of both H1 and H2 antihistamines forms the foundation of MCAS symptom management.
  • • Mast cell stabilizers like cromolyn sodium and ketotifen help prevent cells from releasing inflammatory chemicals.
  • • Patients with hEDS often require compounded medications due to severe sensitivities to standard pill fillers and dyes.
  • • New medications should always be introduced one at a time and titrated slowly to monitor for unexpected reactions.

Unlike standard allergies, which are usually managed by avoiding known triggers and using acute rescue medications, Mast Cell Activation Syndrome (MCAS) requires a continuous, multi-layered pharmacological approach. In patients with hypermobile Ehlers-Danlos Syndrome (hEDS), MCAS is not driven by a single allergen, but by hyperactive mast cells that constantly release a barrage of inflammatory chemicals. Therefore, the treatment strategy shifts from episodic “rescue” to daily, preventative stabilization to block mediators and keep mast cells calm [1].

How MCAS Differs from Regular Allergies

Standard allergies are IgE-mediated, meaning the body has formed specific antibodies against a clear trigger (like peanut protein or pollen). When exposed to that exact trigger, mast cells degranulate (burst) [2]. In idiopathic MCAS, the mast cells degranulate chronically and episodically without established, antigen-specific IgE triggers [3][2].

Because standard allergies are predictable, they are primarily managed through strict avoidance and carrying rescue medications like epinephrine [4]. For hEDS patients with MCAS, triggers are often unavoidable (such as temperature changes, stress, or even digestion), making continuous symptom monitoring and proactive, daily pharmacological intervention necessary [1][5].

First-Line Defense: The Histamine Blockade

The foundation of MCAS treatment relies on constantly blocking the histamine receptors in the body. While seasonal allergy sufferers might take an over-the-counter pill as needed, MCAS protocols are distinct:

  • Continuous, Scheduled Dosing: H1 and H2 antihistamines are taken daily on a strict schedule to prevent mediator damage before it occurs [6].
  • Supra-Therapeutic Dosing: MCAS protocols frequently necessitate higher-than-normal (supra-therapeutic) dosages of antihistamines to achieve symptom control [7][8]. For example, a specialist might prescribe taking a standard “24-hour” allergy pill twice a day, ensuring the receptors never become unblocked.
  • Dual Blockade: Patients typically take both H1 blockers (like cetirizine or fexofenadine) and H2 blockers (like famotidine). While H2 blockers are traditionally known as antacids, histamine receptors are located throughout the body. Blocking both types mitigates multi-organ symptoms, and H2 blockers are particularly effective at managing the severe gastrointestinal issues common in MCAS [9][10][7].

Second-Line Therapies: Stabilizers and Inhibitors

For most patients in the hEDS/POTS/MCAS cluster, antihistamines alone are not enough [6]. When initial antihistamines fail to control symptoms, doctors utilize a stepwise approach to introduce medications that prevent mast cells from breaking apart in the first place, or that target mediators other than histamine [11][12].

  • Mast Cell Stabilizers: These drugs strengthen the outer membrane of the mast cell so it cannot easily rupture. Cromolyn sodium is often administered as an oral liquid, particularly for gastrointestinal symptoms [13]. Because it is poorly absorbed, it typically must be taken strictly on an empty stomach (30 minutes before meals and away from other medications). Due to the risk of symptom flares, it requires careful upward titration from a very low starting dose. Ketotifen, a dual-action mast cell stabilizer and H1 blocker, is another cornerstone therapy. Because it can cause significant sedation, it also requires individualized, cautious dosage titration [14][4].
  • Leukotriene Inhibitors: Histamine is only one of hundreds of chemicals released by mast cells. Leukotrienes cause severe inflammation and smooth muscle contraction. Medications like montelukast are often added to specifically block these pathways [4][11].
  • Supportive Adjuncts: While comprehensive clinical guidelines are limited, many patients integrate over-the-counter natural mast cell stabilizers, such as Quercetin or Vitamin C, into their daily regimens as supportive options alongside prescription therapies [15][4].

Advanced Therapies and hEDS Considerations

Clinical management of MCAS is highly individualized because no two patients react exactly alike [16][17]. If the first and second lines of defense are ineffective, specialists may escalate to biologic medications like omalizumab (Xolair), a monoclonal antibody sometimes used off-label to reduce symptom burden in severe, refractory cases [18][19].

Crucially, treating MCAS within the hEDS comorbidity cluster requires extreme caution. Patients with this cluster frequently exhibit severe sensitivities to excipients—the fillers, dyes, and binders used in standard pills [20][21]. For this reason, many patients utilize compounding pharmacies to have their medications custom-made without problematic ingredients.

Treatment must be a careful process of trial and error. Best practices dictate introducing only one new medication at a time, often starting at a fraction of the standard dose, and monitoring for paradoxical (unexpected negative) reactions [20][22]. Managing overlapping issues, such as POTS-related dysautonomia or delayed gut motility, is also vital, as untreated comorbidities can constantly re-trigger mast cell activation [23][24].

Frequently Asked Questions

How is treating MCAS different from treating regular allergies?
Unlike regular allergies that rely on rescue medications when exposed to a specific trigger, MCAS requires a continuous, daily medication protocol. This proactive approach focuses on keeping mast cells stabilized to prevent them from constantly releasing inflammatory chemicals.
Why do I need to take both H1 and H2 blockers for MCAS?
Histamine receptors are located throughout your entire body, not just in your respiratory system. Taking both H1 and H2 blockers provides comprehensive systemic control and is particularly important for managing the severe gastrointestinal symptoms common in MCAS.
How do mast cell stabilizers work?
Mast cell stabilizers, such as cromolyn sodium and ketotifen, work by strengthening the outer membrane of your mast cells. This makes the cells less likely to rupture and release the hundreds of inflammatory mediators that cause your symptoms.
Why might I need to get my MCAS medications from a compounding pharmacy?
Many patients with hEDS and MCAS have severe sensitivities to the inactive ingredients, such as fillers, dyes, and binders, used in standard commercial pills. A compounding pharmacy can custom-make your prescribed medications without these triggering ingredients.

Questions for Your Doctor

  • • Do I need to trial supra-therapeutic doses of H1 and H2 blockers, and if so, what is the safe titration schedule for me?
  • • Which specific combination of H1 and H2 blockers is best suited to start with based on my primary symptoms?
  • • What is our rescue plan if I have a paradoxical reaction to a new daily medication?
  • • If I react poorly to a medication, can we send the prescription to a compounding pharmacy to remove specific fillers or dyes?
  • • Would my symptoms benefit more from an oral stabilizer like cromolyn sodium or a systemic one like ketotifen, and how do I time these around my meals?

Questions for You

  • • Have I noticed if my reactions occur to specific, avoidable triggers, or are they seemingly unprovoked and systemic?
  • • Which of my symptoms (e.g., gastrointestinal upset, brain fog, skin flushing) are the most disruptive and need prioritizing in my medication plan?
  • • Have I ever had a paradoxical reaction (an unexpected negative response) to a medication, and did I keep track of the specific brand and fillers?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Diagnosis and Management of Patients With Mast Cell Activation Syndromes: Status 2026.

    Akin C, Gülen T, Castells MC, et al.

    The journal of allergy and clinical immunology. In practice 2026; (14(1)):19-28 doi:10.1016/j.jaip.2025.10.046.

    PMID: 41285202
  2. 2

    Idiopathic mast cell activation syndrome is more often suspected than diagnosed-A prospective real-life study.

    Buttgereit T, Gu S, Carneiro-Leão L, et al.

    Allergy 2022; (77(9)):2794-2802 doi:10.1111/all.15304.

    PMID: 35364617
  3. 3

    Mast cell activation syndrome: is anaphylaxis part of the phenotype? A systematic review.

    Sabato V, Michel M, Blank U, et al.

    Current opinion in allergy and clinical immunology 2021; (21(5)):426-434 doi:10.1097/ACI.0000000000000768.

    PMID: 34292177
  4. 4

    Management of indolent mastocytosis and mast cell activation syndrome: A clinical yardstick.

    Akin C, Butterfield JH, Castells M, Lyons JJ

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2025; (135(4)):466-477 doi:10.1016/j.anai.2025.06.032.

    PMID: 40592381
  5. 5

    [Tryptase: A practical guide for the physician].

    Lobbes H, Reynaud Q, Mainbourg S, et al.

    La Revue de medecine interne 2020; (41(11)):748-755 doi:10.1016/j.revmed.2020.06.006.

    PMID: 32712042
  6. 6

    Management of Mastocytosis and Mast Cell Activation in Children.

    Carter MC, Lange M, Alvarez-Twose I, et al.

    The journal of allergy and clinical immunology. In practice 2026; (14(1)):30-42 doi:10.1016/j.jaip.2025.11.016.

    PMID: 41285204
  7. 7

    Continuous diphenhydramine infusion and imatinib for KIT-D816V-negative mast cell activation syndrome: a case report.

    Malik F, Ali N, Jafri SIM, et al.

    Journal of medical case reports 2017; (11(1)):119 doi:10.1186/s13256-017-1278-3.

    PMID: 28438191
  8. 8

    [NON-CLONAL MAST CELL ACTIVATION SYNDROME: DESCRIPTION OF SERIES OF PATIENTS, DIAGNOSTIC CRITERIA AND TREATMENT].

    Confino-Cohen R, Mekori YA

    Harefuah 2015; (154(8)):507-9, 540.

    PMID: 26480615
  9. 9

    Nonclonal Mast Cell Activation Syndrome: A Growing Body of Evidence.

    Hamilton MJ

    Immunology and allergy clinics of North America 2018; (38(3)):469-481 doi:10.1016/j.iac.2018.04.002.

    PMID: 30007464
  10. 10

    Prevalence and treatment response of neuropsychiatric disorders in mast cell activation syndrome.

    Weinstock LB, Afrin LB, Reiersen AM, et al.

    Brain, behavior, & immunity - health 2025; (48()):101048 doi:10.1016/j.bbih.2025.101048.

    PMID: 40686928
  11. 11

    Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach.

    Lee E, Picard M

    Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2025; (21(1)):49 doi:10.1186/s13223-025-00998-9.

    PMID: 41272881
  12. 12

    Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management.

    Castells M, Butterfield J

    The journal of allergy and clinical immunology. In practice 2019; (7(4)):1097-1106 doi:10.1016/j.jaip.2019.02.002.

    PMID: 30961835
  13. 13

    A Continuous Oral Regimen of High-Dose Cromolyn Sodium Is Effective for Some Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Patients With Mast Cell Activation Syndrome.

    Christoforou ME, van Campen LC, Visser FC, et al.

    Cureus 2026; (18(1)):e102064 doi:10.7759/cureus.102064.

    PMID: 41728426
  14. 14

    Biomechanical outcomes of pharmacological therapies for post-traumatic arthrofibrosis in preclinical animal models: a systematic review and meta-analysis.

    Palacios-Díaz L, González-Garcia ÁA, Sánchez Urgellés P, et al.

    Connective tissue research 2024; (65(4)):265-278 doi:10.1080/03008207.2024.2358351.

    PMID: 38814178
  15. 15

    Mast Cell Activation Disorders.

    Giannetti A, Filice E, Caffarelli C, et al.

    Medicina (Kaunas, Lithuania) 2021; (57(2)) doi:10.3390/medicina57020124.

    PMID: 33573161
  16. 16

    Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review.

    Gülen T, Akin C, Bonadonna P, et al.

    The journal of allergy and clinical immunology. In practice 2021; (9(11)):3918-3928 doi:10.1016/j.jaip.2021.06.011.

    PMID: 34166845
  17. 17

    Clustering of clinical symptoms using large language models reveals low diagnostic specificity of proposed alternatives to consensus mast cell activation syndrome criteria.

    Solomon BD, Khatri P

    The Journal of allergy and clinical immunology 2025; (155(1)):213-218.e4 doi:10.1016/j.jaci.2024.09.006.

    PMID: 39278360
  18. 18

    Use of omalizumab for management of idiopathic anaphylaxis: A systematic review and retrospective case series.

    Kaminsky LW, Aukstuolis K, Petroni DH, Al-Shaikhly T

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2021; (127(4)):481-487 doi:10.1016/j.anai.2021.06.017.

    PMID: 34175498
  19. 19

    Mast Cell-Targeting Therapies in Mast Cell Activation Syndromes.

    Sabato V, Beyens M, Toscano A, et al.

    Current allergy and asthma reports 2024; (24(2)):63-71 doi:10.1007/s11882-023-01123-9.

    PMID: 38217824
  20. 20

    Recognition and Management of Medication Excipient Reactivity in Patients With Mast Cell Activation Syndrome.

    Schofield JR, Afrin LB

    The American journal of the medical sciences 2019; (357(6)):507-511 doi:10.1016/j.amjms.2019.03.005.

    PMID: 31126513
  21. 21

    Successful treatment of idiopathic mast cell activation syndrome with low-dose Omalizumab.

    Berry R, Hollingsworth P, Lucas M

    Clinical & translational immunology 2019; (8(10)):e01075 doi:10.1002/cti2.1075.

    PMID: 31576204
  22. 22

    Can H2 -receptor upregulation and raised histamine explain an anaphylactoid reaction on cessation of ranitidine in a 19-year-old female? A case report.

    Allen SJ, Chazot PL, Dixon CJ

    British journal of clinical pharmacology 2018; (84(7)):1611-1616 doi:10.1111/bcp.13578.

    PMID: 29667234
  23. 23

    AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review.

    Aziz Q, Harris LA, Goodman BP, et al.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2025; (23(8)):1291-1302 doi:10.1016/j.cgh.2025.02.015.

    PMID: 40387691
  24. 24

    Complex Presentations, Identification and Treatment of Mast Cell Activation Syndrome and Associated Conditions: A Case Report.

    Quinn AM

    Integrative medicine (Encinitas, Calif.) 2023; (22(4)):36-41.

    PMID: 37752934

This page is for informational purposes only and does not replace professional medical advice. Always consult your healthcare provider or immunologist before starting, stopping, or changing your MCAS medication regimen.

Stay up to date

Get notified when new research about Hypermobile Ehlers-Danlos Syndrome (hEDS) is published.

No spam. Unsubscribe anytime.